$DNAY News
Last published 3y ago
- 3y agoDNAYTBIOTelesis Bio Pre-Announces Preliminary Fourth Quarter Financial ResultsGlobeNewswire-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer leveraging
- 4y agoDNAYTelesis Bio Inc. Reports Third Quarter 2022 Financial ResultsGlobeNewswire-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for
- 4y agoDNAYTelesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrumentGlobeNewswireSAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company, today announced
- 4y agoDNAYCodex DNA Announces Plan to Change Corporate Name to Telesis BioGlobeNewswireSAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced a plan to change its Company name to Telesis Bio. "Our
- 4y agoDNAYCodex DNA Expands Application of Proprietary Error Correction TechnologyGlobeNewswireSAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release of BioXp® Error-corrected Libraries kits that enable researchers to automate synt
- 4y agoDNAYCodex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, NetherlandsGlobeNewswireSAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, will showcase its recently released BioXp™ 9600 system at the World of Technology & Science conference which begi
- 4y agoDNAYCodex DNA Debuts Next-Generation Automated Synthetic Biology WorkstationGlobeNewswireSAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release and first shipment of the BioXp™ 9600 system, a next-generation high throughpu
- 4y agoDNAYCodex DNA Reports Second Quarter 2022 Financial ResultsGlobeNewswireSAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022. Recent HighlightsContinued execution
- 4y agoDNAYCodex DNA, Inc. (DNAY) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsDNAY earnings call for the period ending June 30, 2022.
- 4y agoDNAYCodex DNA to Present at the 2022 Jefferies Healthcare ConferenceGlobeNewswireSAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company's chief executive officer, will present at the 2022 Jefferies H
- 4y agoDNAYCodex DNA Showcases Automated Synthetic Biology Solutions for Accelerating Discovery Workflows at the Antibody Engineering and Therapeutics Europe ConferenceGlobeNewswireBioXp™ system and RapidAMP™ cell-free DNA kit rapidly accelerate antibody discovery pipelines by addressing critical bottlenecks associated with lead candidate gene synthesis, cloning, and scale-up SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Co
- 4y agoDNAYCodex DNA Reports First Quarter 2022 Financial ResultsGlobeNewswireSAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the first quarter ended March 31, 2022. "In the first quarter of 2022, we deli
- 4y agoDNAYCodex DNA, Inc. (DNAY) Q1 2022 Earnings Call TranscriptEarnings Call TranscriptsDNAY earnings call for the period ending March 31, 2022.
- 4y agoDNAYCodex DNA to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022GlobeNewswireSAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its first quarter 2022 financial results on Tuesday, May 10, 2022, after the mark
- 4y agoDNAYCodex DNA Unveils Automated Synthetic Biology Solutions for Antibody and Protein Engineering of Biotherapeutic Targets at 18th Annual PEGS Boston Conference and ExpoGlobeNewswireSAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker lineup for presentations at the PEGS Boston Conference and Expo, which is being held on
- 4y agoDNAYCodex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNAGlobeNewswireSAN DIEGO, April 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the completion of proof-of-concept demonstrations showing that its technology can be used effectivel
- 4y agoDNAYCodex DNA Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development at World Vaccine Congress Washington 2022GlobeNewswireSAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker presentation for the World Vaccine Congress Washington 2022, which is being held in Wash
- 4y agoDNAYCodex DNA to Showcase Innovative SOLA Enzymatic DNA Synthesis Technology and Automated Benchtop BioXp System at SynBioBeta's Built with Biology Global ConferenceGlobeNewswireSAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker lineup for presentations at SynBioBeta's Built with Biology Global Conference, which i
- 4y agoDNAYCodex DNA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 GuidanceGlobeNewswireSAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided financial guid
- 4y agoDNAYCodex DNA, Inc. (DNAY) Q4 2021 Earnings Call TranscriptEarnings Call TranscriptsDNAY earnings call for the period ending December 31, 2021.
- 4y agoDNAYCodex DNA Announces Registration and Webcast Information for Upcoming R&D Webinar on March 29, 2022GlobeNewswireSAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced details for its first Investor R&D Webinar. Management will describe the future promise of the compa
- 4y agoDNAYCodex DNA to Report Fourth Quarter 2021 Financial Results on Tuesday, March 22, 2022GlobeNewswireSAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its fourth quarter 2021 financial results on Tuesday, March 22, 2022, after the
- 4y agoDNAYCodex DNA to Present at the Cowen 42nd Annual Healthcare ConferenceGlobeNewswireSAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company's chief executive officer, will present virtually at the 42nd A
- 4y agoDNAYCodex DNA to Participate in the SVB Leerink 11th Annual Global Healthcare ConferenceGlobeNewswireSAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that members of its management team will be participating in the SVB Leerink 11th Annual Global Healt
- 4y agoDNAYCodex DNA Showcases Potential of Groundbreaking SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Vaccines and TherapeuticsGlobeNewswireProprietary short oligo ligation assembly (SOLA) technology used to enzymatically synthesize DNA fragments for the construction of full-length H1 and N1 genes from influenza A virus Initial performance results show potentially significant quality, time
- 4y agoAVGRBCRXDNAYRELI+1Thinking about buying stock in Tilray, Avinger, Reliance Global, BioCryst Pharmaceuticals, or Codex DNA?PR NewswireNEW YORK, Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TLRY, AVGR, RELI, BCRX, and DNAY.
- 4y agoDNAYCodex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA's Novel Enzymatic DNA Synthesis Technology for Pfizer's use in its Research and Development of mRNA-based Vaccines and BiotherapiesGlobeNewswirePfizer and Codex DNA agree to strategic, multiyear, early access research collaboration, leveraging Codex DNA's novel enzymatic DNA synthesis (EDS) technology Pfizer's successful development and commercialization of licensed products could result in mi
- 4y agoDNAYFTKKPRXNAKD+1Thinking about buying stock in Kiora Pharmaceuticals, Tencent Music Entertainment, Naked Brand, Flotek Industries, or Codex DNA?PR NewswireNEW YORK, Dec. 31, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KPRX, TME, NAKD, FTK, and DNAY. T
- 4y agoDNAYEFOIHIMXISIG+1Thinking about buying stock in Insignia Systems, Codex DNA, Energy Focus, Himax Technologies, or TRACON Pharmaceuticals?PR NewswireNEW YORK, Dec. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISIG, DNAY, EFOI, HIMX, and TCON.
- 4y agoDNAYFTKMFINNRXP+1Thinking about buying stock in Flotek Industries, NRX Pharmaceuticals, Medallion Financial, Reliance Global, or Codex DNA?PR NewswireNEW YORK, Dec. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FTK, NRXP, MFIN, RELI, and DNAY. T
- 4y agoDNAYCodex DNA Expands Catalog of COVID-19 Tools with Release of Full-Length Synthetic Genome for SARS-CoV-2 Omicron VariantGlobeNewswireSAN DIEGO, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the release of a new full-length synthetic genome of the SARS-CoV-2 virus for the highly mutated and
- 4y agoDNAYMRVICodex DNA Announces Commercial Availability of Automated mRNA Synthesis Kit with Integrated Capping Technology for BioXp™ SystemGlobeNewswireProven CleanCap® reagent technology from TriLink BioTechnologies delivers significant time and cost savings for mRNA-based vaccine and therapeutic applications Codex DNA scientists to share latest data and showcase mRNA synthesis solutions at upcoming
- 4y agoDNAYCodex DNA and RNAimmune Announce Collaboration to Optimize Development of Future mRNA Synthesis and Delivery KitsGlobeNewswireSan Diego, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, and RNAimmune, a leading biotech company with expertise in messenger RNA (mRNA) design and delivery technologies,
- 5y agoDNAYCodex DNA to Present at the Jefferies London Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company's chief executive officer, will present virtually at the 12th
- 5y agoDNAYCodex DNA Reports Third Quarter 2021 Financial ResultsGlobeNewswireSAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the third quarter ended September 30, 2021. "Our passion for innovation and
- 5y agoDNAYCodex DNA Acquires Eton BioscienceGlobeNewswireSAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, announced today that it has agreed to acquire Eton Bioscience, a privately held provider of synthetic biology product
- 5y agoDNAYCodex DNA, Inc. (DNAY) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsDNAY earnings call for the period ending September 30, 2021.
- 5y agoDNAYCodex DNA to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021GlobeNewswireSAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its third quarter 2021 financial results on Tuesday, November 9, 2021, after the
- 5y agoDNAYMEDIA ALERT: Codex DNA Customer to Highlight Advantages of Automated BioXp™ System in Precision Cancer Immunotherapy Applications at 13th Annual PEGS Europe Protein and Antibody Engineering SummitGlobeNewswireSan Diego, CA, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that one of its customers will be presenting data at the upcoming PEGS Europe Protein and Antibod
- 5y agoDNAYCodex DNA Releases Full-Length Synthetic Genome for Highly Infectious SARS-CoV-2 Delta VariantGlobeNewswireSan Diego, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the release of its first full-length synthetic genome for the highly infectious Delta variant of
- 5y agoDNAYCodex DNA Reports Second Quarter 2021 Financial ResultsGlobeNewswireSAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2021. "During the second quarter, Codex DNA
- 5y agoDNAYCodex DNA, Inc. (DNAY) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsDNAY earnings call for the period ending June 30, 2021.
- 5y agoDNAYCodex DNA Announces Synthetic Biology Collaboration with U.S. Department of Agriculture to Combat Citrus Greening DiseaseGlobeNewswireSAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced a collaboration with researchers from the U.S. Department of Agriculture's (USDA) Agricultural Resear
- 5y agoDNAYCodex DNA to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021GlobeNewswireSAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), the pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2021 financial results on Tuesday, August 10, 2021. Company
- 5y agoDNAYMRVICodex DNA Announces Licensing and Supply Deal with TriLink Biotechnologies for CleanCap® mRNA Capping TechnologyGlobeNewswireSAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced a licensing and supply agreement with TriLink Biotechnologies, part of Maravai LifeSciences (NASDAQ:M
- 5y agoDNAYCodex DNA Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewswireSAN DIEGO, June 22, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY) today announced the closing of its initial public offering of 7,666,664 shares of common stock, including the full exercise of the underwriters' option to purchase up to 999,999
- 5y agoDNAYCodex DNA Announces Pricing of Initial Public OfferingGlobeNewswireSAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. ("Codex DNA"), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today announced the pricing of its initial public offe
- 5y agoDNAYCodex DNA Announces Launch of Initial Public OfferingGlobeNewswireSAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. ("Codex DNA"), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today announced the launch of its public offering of 6